Clinical Trial

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Study acronym: MALBEC
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Protocol Amendment History 8 changes
notable Trial sites expanded: 91 -> 97 locations 2026-08-07
notable Trial sites expanded: 87 -> 91 locations 2026-07-25
notable Trial sites expanded: 71 -> 87 locations 2026-07-11
notable Trial sites expanded: 42 -> 71 locations 2026-07-01
notable Trial sites expanded: 30 -> 42 locations 2026-06-16
notable Trial sites expanded: 20 -> 30 locations 2026-05-05
critical Recruitment opened 2026-04-16
notable Trial sites expanded: 0 -> 20 locations 2026-04-16
Trial Details
NCT Number NCT07440225
Lead Sponsor EyeBiotech Ltd.
Conditions Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Enrollment 960 participants
Start Date 2026-03-27
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06